IART — Integra LifeSciences Holdings Corporation stock price and chart

IART

$13.33-0.89%

as of close, Oct 20, 2026

☾ AH $13.33 -0.89%

Integra LifeSciences Holdings CorporationStock · HealthcareRussell 2000 · 0.04% of IWMRussell 3000 · 0.002% of IWVUS Stock Market · 0.002% of VTI

PeersMRNALLYMDTUNHJNJTMO

Share this page

Technical analysis2

Overlay lines0

Addendum charts0

VolumeSEEEEEEEEEEEE

20162019202120242026

10.020.030.040.050.060.070.0010.0M$13.33

2026-10-20

Price$13.33

MA20$16.24

MA50$13.92

Vol4.2M

What would $1,000 invested in IART be worth today? →

IART returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $13.33
YTD price return: +7.33%
YTD total return: +7.33%
Next earnings: Oct 21, 2026 · Before open
Market cap: 1B2016-12 3.2B2026-10 1B-67.7% over the window
Enterprise value: 1.6B
Shares outstanding: 77.8M2016-06 74.7M2026-06 77.8M+4.1% over the window
52W low: $8.70
52W high: $20.49
From 52W high: -34.94%
From 52W low: +53.22%
52W range: 39%

Volume

Rel volume: 1.17×
30D volume: 1.1M
30D $ vol: 16.2M

Fundamentals

Sales (ttm): 1.6B2016-12 992.1M2026-06 1.6B+66.1% over the window
Sales/share: $21.192016-12 $13.262026-06 $21.19+59.8% over the window
EPS (ttm): -$0.092016-06 $0.092026-06 -$0.09-204.3% over the window
FCF (ttm): 25.8M2016-06 70.7M2026-06 25.8M-63.5% over the window
FCF/share: $0.332016-06 $0.952026-06 $0.33-65.0% over the window
Book value/share: $13.422016-06 $10.642026-06 $13.42+26.1% over the window
Net margin: -0.44%2016-12 7.5%2026-06 -0.4%-105.8% over the window
ROE: -0.69%2016-06 1.2%2026-06 -0.7%-159.5% over the window
ROA: -0.20%2016-06 0.5%2026-06 -0.2%-139.8% over the window
Debt / equity: 0.68×2018-03 1.192026-06 0.68-42.9% over the window
Current ratio: 3.602016-06 3.302026-06 3.60+9.2% over the window

Growth (CAGR, ttm) · 10Y

Sales: +1.60%2025-06-30 → 2026-06-301.6B → 1.6B (+1.6% total)+2.16%2023-06-30 → 2026-06-301.5B → 1.6B (+6.6% total)+1.77%2021-06-30 → 2026-06-301.5B → 1.6B (+9.2% total)+5.49%2016-12-31 → 2026-06-30992.1M → 1.6B (+66.1% total)
FCF: n/a-45.01%2023-06-30 → 2026-06-30155.2M → 25.8M (-83.4% total)-38.01%2021-06-30 → 2026-06-30281.8M → 25.8M (-90.8% total)-9.59%2016-06-30 → 2026-06-3070.7M → 25.8M (-63.5% total)
Shares: -0.18%2025-06-30 → 2026-06-3077.9M → 77.8M (-0.2% total)-1.51%2023-06-30 → 2026-06-3081.4M → 77.8M (-4.5% total)-1.66%2021-06-30 → 2026-06-3084.6M → 77.8M (-8.0% total)+0.40%2016-06-30 → 2026-06-3074.7M → 77.8M (+4.1% total)

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +1.78%2025-06-30 → 2026-06-30$20.82 → $21.19 (+1.8% total)+3.73%2023-06-30 → 2026-06-30$18.98 → $21.19 (+11.6% total)+3.50%2021-06-30 → 2026-06-30$17.84 → $21.19 (+18.8% total)+5.06%2016-12-31 → 2026-06-30$13.26 → $21.19 (+59.8% total)
FCF/share: n/a-44.17%2023-06-30 → 2026-06-30$1.91 → $0.33 (-82.6% total)-36.96%2021-06-30 → 2026-06-30$3.33 → $0.33 (-90.0% total)-9.96%2016-06-30 → 2026-06-30$0.95 → $0.33 (-65.0% total)
Book value/share: +0.63%2025-06-30 → 2026-06-30$13.33 → $13.42 (+0.6% total)-13.43%2023-06-30 → 2026-06-30$20.68 → $13.42 (-35.1% total)-6.35%2021-06-30 → 2026-06-30$18.62 → $13.42 (-28.0% total)+2.35%2016-06-30 → 2026-06-30$10.64 → $13.42 (+26.1% total)
Price: -15.05%2025-10-20 → 2026-10-20$15.69 → $13.33 (-15.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-29.43%2023-10-20 → 2026-10-20$37.94 → $13.33 (-64.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-28.19%2021-10-20 → 2026-10-20$69.81 → $13.33 (-80.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-10.53%2016-10-19 → 2026-10-20$40.56 → $13.33 (-67.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: -15.05%2025-10-20 → 2026-10-20$15.69 → $13.33 (-15.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-29.43%2023-10-20 → 2026-10-20$37.94 → $13.33 (-64.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-28.19%2021-10-20 → 2026-10-20$69.81 → $13.33 (-80.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-10.53%2016-10-19 → 2026-10-20$40.56 → $13.33 (-67.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -142.0×2016-12 52.322026-10 -143.13-373.6% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 15.8×2016-12 32.542026-10 15.81-51.4% over the window
Fwd P/E: 5.3×
P/S (ttm)Market cap ÷ TTM revenue.: 0.6×2017-03 3.142026-10 0.63-80.0% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 1.0×2016-12 3.902026-10 0.99-74.5% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 40.2×2016-12 33.312026-10 40.18+20.6% over the window
EV/Sales (ttm): 1.0×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 2.49%2016-09 3.0%2026-06 1.8%-38.5% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 77.8M ÷ 77.9M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 0.18%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (0.18%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($956M). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 0.18%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($1B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2016-09 0.0%2026-06 0.0%-100.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($1B). Same caveat as the cash buyback yield.: 0.00%2016-09 0.0%2026-06 0.0%-100.0% over the window

Vs own 10Y history

P/E: 62nd
P/OI: 2nd
P/S: 7th
P/B: 10th
P/FCF: 58th

Bar = where today’s multiple sits in IART’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-20#

-0.89%

-3.75%

-12.42%

-29.43%

YTD

+7.33%

-15.04%

-80.91%

Financial statements

Open full IART financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+11.34%	+3.49%
JNJ	Johnson & Johnson	-3.94%	+2.19%
ABBV	AbbVie Inc.	+9.52%	+2.26%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+11.24%	+3.04%
MRK	Merck & Co. Inc.	+0.97%	+3.25%
NVS	Novartis AG	+9.45%	+2.29%
TMO	Thermo Fisher Scientific Inc.	+5.51%	+1.18%
AMGN	Amgen Inc.	+13.82%	+3.29%

IART — Integra LifeSciences Holdings Corporation price, chart and key statistics